Skip to main content
PMC home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Aug;89(8):870–880. doi: 10.1111/j.1349-7006.1998.tb00642.x

Rhenium‐186‐mercaptoacetyltriglycine‐labeled Monoclonal Antibody for Radioimmunotherapy: In vitro Assessment, in vivo Kinetics and Dosimetry in Tumor‐bearing Nude Mice

Seigo Kinuya 1,✉, Kunihiko Yokoyama 1, Harunobu Tega 1, Takashi Hiramatsu 1, Shota Konishi 1, Wakako Yamamoto 2, Noriyuki Shuke 2, Tamio Aburano 2, Naoto Watanabe 3, Terahiko Takayama 4, Takatoshi Michigishi 1, Norihisa Tonami 1
PMCID: PMC5921918  PMID: 9765625

Abstract

Stability and immunoreactivity of 186Re‐labeled monoclonal antibody were examined, and its in vivo kinetics was investigated in tumor‐bearing Balb/c nu/nu female mice to assess the feasibility of using it in radioimmunotherapy (RIT). A murine IgG1, A7, against a 45 kD glycoprotein in human colon cancer was radiolabeled with 186Re by using a chelating method with a mercaptoacetyltriglycine (MAG3). 186Re‐MAG3 complex was conjugated to A7 after esterification of 186Re‐MAG3 with tetrafluorophenol (TFP). The efficiency of 186Re‐MAG3‐TFP production and the labeling efficiency of A7 were 51–59% and 57–60%, respectively. Immunoreactivity of purified 186Re‐MAG3‐A7 was 68.2% at infinite antigen excess. In 0.9% NaCl at 4°C, the radioactivity (12.7 MBq/mg, 3.55 MBq/ml) dissociated with time from 186Re‐MAG3‐A7 as a small molecular weight moiety because of autoradiolysis. The addition of ascorbic acid, 5 mg/ml, as a radioprotectant or storage at –80°C could effectively prevent the radiolysis of 186Re‐MAG3‐A7 for 7 days. Immunoreactivity of 186Re‐MAG3‐A7, 6.70 MBq/mg (6.66 MBq/ml), stored in the presence of ascorbic acid was well retained up to 8 days after the preparation. In colon cancer xenografted mice, 31.0% of the injected dose/g of 186Re‐MAG3‐A7 had accumulated in the tumors at 24 h postinjection. Estimated radiation dose to tumors was 14.9 cGy/37 kBq up to 8 days postinjection which was 12‐fold greater than the whole‐body radiation dose. These in vivo characteristics were superior to those of A7 labeled with radioiodine, affording greater therapeutic ratios than 131I‐A7. Because of the better image quality of 186Re‐MAG3‐A7 as well as more favorable dosimetry, 186Re‐MAG3‐A7 would be a better choice for RIT of colon cancer than 131I‐A7. These results indicated the feasibility of RIT with 186Re‐MAG3‐A7, though the prevention of radiolysis of the labeled antibody should be considered.

Keywords: key words, Monoclonal antibody, Rhenium‐186, Autoradiolysis, Biodistribution, Dosimetry

Full Text

The Full Text of this article is available as a PDF (120.1 KB).

We thank Dr. Yasushi Arano, Faculty of Pharmaceutical Sciences, Kyoto University, for providing S‐benzoyl‐MAG3, and Prof. Toshio Takahashi and Dr. Toshiharu Yamaguchi, First Department of Surgery, Kyoto Prefectural University of Medicine, for A7 mAb.

REFERENCES

  • 1. ) Kaminski , M. S. , Zasadny , K. R. , Francis , I. R. , Milik , A. W. , Ross , C. W. , Moon , S. D. , Crawford , S. M. , Burgess , J. M. , Petry , N. A. , Butchko , G. M. , Glenn , S. D. and Wahl , R. L.Radioimmunotherapy of B‐cell lymphoma with [131I]anti‐B1 (anti‐CD20) antibody . N. Engl. J. Med. , 329 , 459 – 465 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Press , O. W. , Eary , J. F. , Appelbaum , F. R. , Martin , P. J. , Badger , C. C. , Nelp , W. B. , Glenn , S. , Butchko , G. , Fisher , D. , Porter , B. , Matthews , D. C. , Fisher , L. D. and Berstein , I. D.Radiolabeled‐antibody therapy of B‐cell lymphoma with autologous bone marrow support . N. Engl. J. Med. , 329 , 1219 – 1224 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Naruki , Y. , Carrasquillo , J. A. , Reynolds , J. C. , Maloney , P. J. , Frincke , J. M. , Neumann , R. D. and Larson , S. M.Differential cellular catabolism of 111In, 90Y and 125I radiolabeled T101 anti‐CD5 monoclonal antibody . Nucl. Med. Biol. , 17 , 201 – 207 ( 1990. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Yokoyama , K. , Carrasquillo , J. A. , Chang , A. E. , Colcher , D. , Roselli , M. , Sugarbaker , P. , Sindelar , W. , Reynolds , J. C. , Perentesis , P. , Gansow , O. A. , Francis , B. , Adams , R. , Finn , R. , Schlom , J. and Larson , S. M.Differences in bio‐distribution of indium‐111‐ and iodine‐131‐labeled B72.3 monoclonal antibodies in patients with colorectal cancer . J. Nucl. Med. , 30 , 320 – 327 ( 1989. ). [PubMed] [Google Scholar]
  • 5. ) Camera , L. , Kinuya , S. , Garmestani , K. , Brechbiel , M. W. , Wu , C. , Pai , L. H. , McMurry , T. J. , Gansow , O. A. , Pastan , I. , Paik , C. H. and Carrasquillo , J. A.Comparative biodistribution of indium‐ and yttrium‐labeled B3 monoclonal antibody conjugated to either 2‐(p‐SCN‐Bz)‐6‐methyl‐DTPA (1B4M‐DTPA) or 2‐(p‐SCN‐Bz)‐1,4,7,10‐tetraaza‐cyclododecane tetraacetic acid (2B‐DOTA) . Eur. J. Nucl. Med. , 21 , 640 – 646 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Camera , L. , Kinuya , S. , Garmestani , K. , Wu , C. , Brechbiel , M. W. , Pai , L. H. , McMurry , T. J. , Gansow , O. A. , Pastan , I. , Paik , C. H. and Carrasquillo , J. A.Evaluation of the serum stability and in vivo biodistribution of CHX‐DTPA and other ligands for yttrium labeling of monoclonal antibodies . J. Nucl. Med. , 35 , 882 – 889 ( 1994. ). [PubMed] [Google Scholar]
  • 7. ) Deshpande , S. V. , DeNardo , S. J. , Kukis , D. L. , Moi , M. K. , McCall , M. J. , DeNardo , G. L. and Meares , C. F.Yttrium‐90‐labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent . J. Nucl. Med. , 31 , 473 – 479 ( 1990. ). [PubMed] [Google Scholar]
  • 8. ) Sharkey , R. M. , Motta‐Hennessy , C. , Pawlyk , D. , Siegel , J. A. and Goldenberg , D. M.Biodistribution and radiation dose estimates for yttrium‐ and iodine‐labeled monoclonal antibody IgG and fragments in nude mice bearing human colonic tumor xenografts . Cancer Res. , 50 , 2330 – 2336 ( 1990. ). [PubMed] [Google Scholar]
  • 9. ) Kosmas , C. , Maraveyas , A. , Gooden , C. S. , Snook , D. and Epenetos , A. A.Anti‐chelate antibodies after intraperitoneal yttrium‐90‐labeled monoclonal antibody immunocon‐jugates for ovarian cancer therapy . J. Nucl. Med. , 36 , 746 – 753 ( 1995. ). [PubMed] [Google Scholar]
  • 10. ) Behr , T. M. , Becker , W. S. , Bair , H.‐J. , Klein , M. W. , Stühler , C. M. , Cidlinsky , K. P. , Wittekind , C. W. , Scheele , J. R. and Wolf , F. G.Comparison of complete versus fragmented technetium‐99m‐labeled anti‐CEA monoclonal antibodies for immunoscintigraphy in colorectal cancer . J. Nucl. Med. , 36 , 430 – 441 ( 1995. ). [PubMed] [Google Scholar]
  • 11. ) Oriuchi , N. , Endo , K. , Watanabe , N. , Sugiyama , S. , Asao , T. , Takenoshita , S. , Nagamachi , Y. and Baum , R. P.Semi‐quantitative SPECT tumor uptake of technetium‐99m‐labeled anti‐CEA monoclonal antibody in colorectal tumor . J. Nucl. Med. , 36 , 679 – 683 ( 1995. ). [PubMed] [Google Scholar]
  • 12. ) Griffiths , G. L. , Goldenberg , D. M. , Knapp , F. F. , Jr. , Callahan , A. P. and Chang , C.‐H.Direct radiolabeling of monoclonal antibodies with generator‐produced rhenium‐188 for radioimmunotherapy: labeling and animal biodistribution studies . Cancer Res. , 51 , 4594 – 4602 ( 1991. ). [PubMed] [Google Scholar]
  • 13. ) Fritzberg , A. R.Advances in 99mTc‐labeling of antibodies . Nucl. Med. , 26 , 7 – 12 ( 1987. ). [PubMed] [Google Scholar]
  • 14. ) Najafi , A. , Alauddin , M. M. , Sosa , A. , Ma , G. Q. , Chen , D. C. P. , Epstein , A. L. and Siegel , M. E.The evaluation of 186Re‐labeled antibodies using N2S4 chelate in vitro and in vivo using tumor‐bearing nude mice . Nucl. Med. Biol. , 19 , 205 – 212 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 15. ) Visser , G. M. W. , Gerretsen , M. , Herscheid , J. D. M. , Snow , G. B. and van Dongen , G.Labeling of monoclonal antibodies with rhenium‐186 using MAG3 chelate for radioimmunotherapy of cancer: a technical protocol . J. Nucl. Med. , 34 , 1953 – 1963 ( 1993. ). [PubMed] [Google Scholar]
  • 16. ) Goldrosen , M. H. , Biddle , W. C. , Pancook , J. , Bakshi , S. , Vanderheyden , J.‐L. , Fritzberg , A. R. , Morgan , A. C. , Jr. and Foon , K. A.Biodistribution, pharmacokinetic, and imaging studies with 186Re‐labeled NR‐LU‐10 whole antibody in LS174T colonic tumor‐bearing mice . Cancer Res. , 50 , 7973 – 7978 ( 1990. ). [PubMed] [Google Scholar]
  • 17. ) Divgi , C. R. , Scott , A. M. , Dantis , L. , Capitelli , P. , Siler , K. , Hilton , S. , Finn , R. D. , Kemeny , N. , Kelsen , D. , Kostakoglu , L. , Schlom , J. and Larson , S. M.Phase I radioimmunotheraphy trial with iodine‐131‐CC49 in meta‐static colon cancer . J. Nucl. Med. , 36 , 586 – 592 ( 1995. ). [PubMed] [Google Scholar]
  • 18. ) Behr , T. M. , Sharkey , R. M. , Juweid , M. E. , Dunn , R. M. , Ying , Z. , Zhang , C.‐H. , Siegel , J. A. and Goldenberg , D. M.Variables influencing tumor dosimetry in radioimmunotherapy of CEA‐expressing cancers with anti‐CEA and antimucin monoclonal antibodies . J. Nucl. Med. , 38 , 409 – 418 ( 1997. ). [PubMed] [Google Scholar]
  • 19. ) Wahl , R. L. , Wissing , J. , del Rosario , R. and Zasadny , K. R.Inhibition of autoradiolysis of radiolabeled monoclonal antibodies by cryopreservation . J. Nucl. Med. , 31 , 84 – 89 ( 1990. ). [PubMed] [Google Scholar]
  • 20. ) Chakrabarti , M. C. , Le , N. , Paik , C. H. , De Graff , W. G. and Carrasquillo , J. A.Prevention of radiolysis of monoclonal antibody during labeling . J. Nucl. Med. , 37 , 1384 – 1388 ( 1996. ). [PubMed] [Google Scholar]
  • 21. ) Kotanagi , H. , Takahashi , T. , Masuko , T. , Hashimoto , Y. and Koyama , K.A monoclonal antibody against human colon cancers . Tohoku J. Exp. Med. , 148 , 353 – 360 ( 1986. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Takahashi , T. , Yamaguchi , T. , Kitamura , K. , Suzuyama , H. , Honda , M. , Yokota , T. , Kotanagi , H. , Takahashi , M. and Hashimoto , Y.Clinical application of monoclonal antibody‐drug conjugates for immunotargeting chemotherapy for colorectal carcinoma . Cancer , 61 , 881 – 888 ( 1988. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Yamaoka , N. , Yamaguchi , T. , Otsuji , E. , Kato , M. , Kotani , T. , Kitamura , K. and Takahashi , T.In vitro reactivity and in vivo biodistribution of the monoclonal antibody A7 using human gastric carcinoma cell lines . Br. J. Cancer , 70 , 405 – 408 ( 1994. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. ) Kinuya , S. , Yokoyama , K. , Konishi , S. , Tonami , N. and Hisada , K.Effect of induced hypertension with angiotensin II infusion on biodistribution of 111In‐labeled monoclonal antibody . Nucl. Med. Biol. , 23 , 137 – 140 ( 1996. ). [DOI] [PubMed] [Google Scholar]
  • 25. ) Lindmo , T. , Boven , E. , Cuttitta , C. , Fedorko , J. and Bunn , P. A. , Jr.Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess . J. Immunol. Methods , 72 , 77 – 89 ( 1984. ). [DOI] [PubMed] [Google Scholar]
  • 26. ) Dillman , L. T.Radionuclide decay schemes and nuclear parameters for use in radiation‐dose estimation . MIRD Pamphlet‐4, The Society of Nuclear Medicine, New York ( 1969. ). [PubMed]
  • 27. ) Gerretsen , M. , Visser , G. W. M. , van Walsum , M. , Meijer , C. J. L. M. , Snow , G. B. and van Dongen , G. A. M. S.186Re‐labeled monoclonal antibody E48 immunoglobulin G‐mediated therapy of human head and neck squamous cell carcinoma xenografts . Cancer Res. , 53 , 3524 – 3529 ( 1993. ). [PubMed] [Google Scholar]
  • 28. ) Buchegger , F. , Pelegrin , A. , Delaloye , B. , Bischof‐Delaloye , A. and Mach , J.‐P.Iodine‐131‐labeled MAb F(ab')2 fragments are more efficient and less toxic than intact anti‐CEA antibodies in radioimmunotherapy of large human colon carcinoma grafted in nude mice . J. Nucl. Med. , 31 , 1035 – 1044 ( 1990. ). [PubMed] [Google Scholar]
  • 29. ) Goldenberg , D. M. and Griffiths , G. L.Radioimmunotherapy of cancer: arming and missiles . J. Nucl. Med. , 33 , 1110 – 1112 ( 1992. ). [PubMed] [Google Scholar]
  • 30. ) van Gog , F. B. , Visser , G. W. M. , Klok , R. , van der Schos , R. , Snow , G. B. and van Dongen , G. A. M. S.Monoclonal antibodies labeled with rhenium‐186 using MAG3 chelate: relationship between the number of chelated groups and biodistribution characteristics . J. Nucl. Med. , 37 , 352 – 362 ( 1996. ). [PubMed] [Google Scholar]
  • 31. ) Kievit , E. , van Gog , F. B. , Schlüper , H. M. M. , van Dongen , G. A. M. S. , Pinedo , H. M. and Boven , E.[186Re]‐labeled mouse and chimeric monoclonal antibody 323/Ab: a comparison of the efficacy in experimental human ovarian cancer . Nucl. Med. Biol. , 25 , 37 – 45 ( 1998. ). [DOI] [PubMed] [Google Scholar]
  • 32. ) Breitz , H. B. , Weiden , P. L. , Vanderheyden , J.‐L. , Appelbaum , J. W. , Bjorn , M. J. , Fer , M. F. , Wolf , S. B. , Ratliff , B. A. , Seiler , C. A. , Foisie , D. C. , Fisher , D. R. , Schroff , R. W. , Fritzberg , A. R. and Abrams , P. G.Clinical experience with rhenium‐186‐labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials . J. Nucl. Med. , 33 , 1099 – 1112 ( 1992. ). [PubMed] [Google Scholar]
  • 33. ) Beaumier , P. L. , Venkatesan , P. , Vanderheyden , J.‐L. , Burgua , W. D. , Kunz , L. L. , Fritzberg , A. R. , Abrams , P. G. and Morgan , A. C. , Jr.186Re radioimmunotherapy of small cell lung carcinoma xenografts in nude mice . Cancer Res. , 81 , 676 – 681 ( 1991. ). [PubMed] [Google Scholar]
  • 34. ) Kinuya , S. , Yokoyama , K. , Konishi , S. , Hiramatsu , T. , Tega , H. , Michigishi , T. and Tonami , N.Induced hypertension and kinin degradation inhibition could benefit radioimmunotherapy in tumor‐xenografted mice . J. Nucl. Med. , 39 , 106P ( 1998. ). [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES